Drug Approval | July 26, 2023
Eugia Pharma receives USFDA approval for Plerixafor Injection
The approved product has an estimated market size of around US$ 210 million for the twelve months ending May 2023
The approved product has an estimated market size of around US$ 210 million for the twelve months ending May 2023
Aurobindo will respond to the US FDA within the stipulated timelines
The product will be produced at the Eugia Pharma Specialities, Unit-I, Medchal, Malkajgiri District, Telangana, India
The product is expected to be launched in June 2023
Venkat Nageswar Chalasani has been appointed as an Independent Director of Apitoria Pharma with effect from April 4, 2023
The approved product is indicated for the treatment of adult patients with Multiple myeloma, in combination with Dexamethasone
Revenue from operations during the quarter was up by 6.7 per cent to Rs 6,407.10 crore against Rs 6,002.2 in the same period last fiscal.
The company has been issued ‘Form 483’ with two observations
Supriya Lifescience Limited has informed that the European Directorate for the Quality of Medicines (EDQM) has granted Attestation of Inspection (EU-GMP) for Lote API Facility, Ratnagiri, Maharashtra.
The product is expected to be launched by Q4 FY23.
Subscribe To Our Newsletter & Stay Updated
